NEW Evidence in First-Line AML & Exploring Outcomes with Fixed-Duration Treatment for CLL

BONS MEMBERS ONLY

Thursday, November 12, 2020, 8:00 PM ET

Vinod Pullarkat, MD Clinical Professor of Hematology & Hematopoietic Cell Transplantation City of Hope Comprehensive Cancer Center, Duarte, CA

Nakhle Saba, MD Associate Professor of Medicine, Section of Hematology and Medical Oncology Tulane University, New Orleans, LA

Follow this link to REGISTER!

https:// abbvie.meintl.com/00071-OB20-20

DURING THIS INTERACTIVE PROGRAM WE WILL:

• Recognize VENCLEXTA as a BCL-2 inhibitor for 1L AML, and 1L and R/R CLL • Review the phase 3 efficacy and safety outcomes of VENCLEXTA + azacitidine from the pivotal VIALE-A study

for patients with 1L AML, ineligible for intensive induction chemotherapy due to age or comorbidities • Explore the efficacy and safety outcomes of VENCLEXTA’s chemo-free, fixed duration CLL regimens

See news and events page for more details.